Medlab Clinical Limited (MDC.AX)
| Previous close | 0.09 |
| Open | 0.09 |
| Bid | 0.09 x 0 |
| Ask | 0.10 x 0 |
| Day's range | 0.09 - 0.09 |
| 52-week range | 0.09 - 30.00 |
| Volume | |
| Avg. volume | 1,815 |
| Market cap | 4.517B |
| Beta (5Y monthly) | 1.29 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.04 |
| Earnings date | 22 Feb 2022 - 28 Feb 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 0.42 |
- Simply Wall St.
What You Need To Know About Medlab Clinical Limited's (ASX:MDC) Investor Composition
Every investor in Medlab Clinical Limited ( ASX:MDC ) should be aware of the most powerful shareholder groups. Large...
- GlobeNewswire
Medlab (ASX:MDC) receives Government grant to apply NanoCelle® to an RNA nasal vaccine in collaboration with University of NSW (UNSW) and Macquarie University (MQ) to fight COVID-19 future potential epidemics
NSW Government grant received on 23rd December 2021 to develop a “no-jab” vaccine solutionMedlab collaborates with UNSW and MQ University (two leading global academic and R&D institutions)This NanoCelle® non-invasive nasal delivered vaccine is considered a “first in class” medicine delivery systemThis Government Grant & Academic collaboration solidify Medlab’s transition to a true Biotech company.Global relevance expectation is extremely highNanoCelle® as an asset is yet to be valued in any anal
- GlobeNewswire
Nanocelle® Patent Granted in Usa
Medlab receives Granted Patent Protection for NanoCelle® in the USA by US Patent & Trademark Office (USPTO) SYDNEY, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Medlab Clinical Ltd (ASX: MDC) is extremely pleased to announce the USPTO has granted patent protection for NanoCelle® “Transmucosal and transdermal delivery systems” (Patent No. 11160753) in the United States of America. This announcement follows just three weeks after announcing the ‘Notice of Allowance’ received by the USPTO. (October 06, 2021).
